Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV GT1b with Cirrhosis
NCT02219503Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of ombitasvir, paritaprevir, ritonavir and dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment. Started Sep 2014; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02219503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219503.